Green Cross Holdings Preference Shares Cash Flow Conversion Efficiency
Green Cross Holdings Preference Shares cash flow conversion efficiency. Based on the latest financial reports, Green Cross Holdings Preference Shares (005257) has a cash flow conversion efficiency ratio of 0.008x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.28 Billion ≈ $9.68 Million USD) by net assets (₩1.74 Trillion ≈ $1.18 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Green Cross Holdings Preference Shares (2013–2025)
Cash flow conversion efficiency of Green Cross Holdings Preference Shares from 2013 to 2025. This chart illustrates how Green Cross Holdings Preference Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Green Cross Holdings Preference Shares share price for real-time trading data and today's change.
Green Cross Holdings Preference Shares Cash Flow Conversion Ratio Explained
Green Cross Holdings Preference Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Green Cross Holdings Preference Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Green Cross Holdings Preference Shares ranked by their cash flow conversion efficiency. Also see Green Cross Holdings Preference Shares stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hensel Davest Indonesia Tbk PT
JK:HDIT
|
0.000x |
|
Dolphin International Bhd
KLSE:5265
|
-0.004x |
|
Prestal Holdings Ltd
AU:PTL
|
-0.192x |
|
Public Policy Holding Company Inc
LSE:PPHC
|
0.024x |
|
Arkadia Digital Media Tbk PT
JK:DIGI
|
0.084x |
|
LakeShore Biopharma Co., Ltd
NYSE:LSBCF
|
-0.001x |
|
Australian Silica Quartz Group Ltd
F:4B4
|
-0.076x |
|
Uni-Fuels Holdings Limited Class A Ordinary Shares
NASDAQ:UFG
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Green Cross Holdings Preference Shares (2013–2025)
The table below shows the annual cash flow conversion efficiency of Green Cross Holdings Preference Shares from 2013 to 2025. Review 005257 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩1.76 Trillion ≈ $1.20 Billion |
₩24.30 Billion ≈ $16.47 Million |
0.014x | +128.37% |
| 2024-12-31 | ₩1.85 Trillion ≈ $1.26 Billion |
₩-89.95 Billion ≈ $-60.96 Million |
-0.049x | -130.42% |
| 2023-12-31 | ₩1.88 Trillion ≈ $1.28 Billion |
₩-39.65 Billion ≈ $-26.87 Million |
-0.021x | -142.67% |
| 2022-12-31 | ₩1.97 Trillion ≈ $1.33 Billion |
₩97.16 Billion ≈ $65.84 Million |
0.049x | -9.05% |
| 2021-12-31 | ₩1.91 Trillion ≈ $1.29 Billion |
₩103.77 Billion ≈ $70.32 Million |
0.054x | +154.07% |
| 2020-12-31 | ₩1.67 Trillion ≈ $1.13 Billion |
₩35.77 Billion ≈ $24.24 Million |
0.021x | +320.95% |
| 2019-12-31 | ₩1.51 Trillion ≈ $1.02 Billion |
₩7.65 Billion ≈ $5.18 Million |
0.005x | -80.40% |
| 2018-12-31 | ₩1.45 Trillion ≈ $984.76 Million |
₩37.64 Billion ≈ $25.51 Million |
0.026x | -74.19% |
| 2017-12-31 | ₩1.44 Trillion ≈ $975.64 Million |
₩144.48 Billion ≈ $97.91 Million |
0.100x | +17256.99% |
| 2016-12-31 | ₩1.38 Trillion ≈ $933.18 Million |
₩-805.47 Million ≈ $-545.86K |
-0.001x | -110.87% |
| 2015-12-31 | ₩1.31 Trillion ≈ $885.99 Million |
₩7.04 Billion ≈ $4.77 Million |
0.005x | -88.35% |
| 2014-12-31 | ₩1.18 Trillion ≈ $800.39 Million |
₩54.54 Billion ≈ $36.96 Million |
0.046x | +189.06% |
| 2013-12-31 | ₩1.10 Trillion ≈ $745.23 Million |
₩17.57 Billion ≈ $11.91 Million |
0.016x | -- |
About Green Cross Holdings Preference Shares
GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and… Read more